Keywords: BB; bevacizumab-bevacizumab; BP; bevacizumab followed by panitumumab; CA9; carbonic anhydrase 9; CRC; colorectal cancer; DEGs; differentially expressed genes; EGFR; epidermal growth factor receptor; EPHA2; ephrin type-A receptor 2; FASN; fatty acid syntha
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Capecitabine; FOLFIRI; FOLFOX; mCC; Outcomes;
Keywords: 5-Fluorouracil; FOLFIRI; FOLFOX; Leucovorin; 5,10-Methylenetetrahydrofolate;
Keywords: Antibodies; Immunoconjugates; Immunotoxins; Ab; antibody; Ag; antigen; ADCC; antibody-dependent cell mediated cytotoxicity; ALL; acute lymphoblastic leukemia; AML; acute myeloid leukemia; AKT; protein kinase B; APC; antigen-presenting cell; Apo2L/TRAIL; t
Keywords: Metastatic colorectal cancer; Irinotecan; Oxaliplatin; Cetuximab; Bevacizumab; Chemotherapy regimen sequencing; FOLFIRI; FOLFOX
Evaluating bevacizumab in combination with FOLFIRI after the failure of platinum-etoposide regimen in patients with advanced poorly differentiated neuroendocrine carcinoma: The PRODIGE 41-BEVANEC randomized phase II study
Keywords: Bevacizumab; Clinical trial; FOLFIRI; Gastroenteropancreatic; Neuroendocrine carcinoma;
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial
Keywords: Colon cancer; Toxicity; UGT1A1; FOLFIRI;
Prognostic value of radiologically enlarged lymph nodes in patients with metastatic colorectal cancer: Subgroup findings of the randomized, open-label FIRE-3/AIO KRK0306 trial
Keywords: AJCC; American Joint Committee on Cancer; AP; alkaline phosphatase; BRAF; v-Raf murine sarcoma viral oncogene homolog B; CI; confidence interval; CRC; (colorectal cancer); CT; computed tomography; ECOG; Eastern Cooperative Oncology Group scale of performa
Natural small molecule bigelovin suppresses orthotopic colorectal tumor growth and inhibits colorectal cancer metastasis via IL6/STAT3 pathway
Keywords: ALT; alanine aminotransferase; AST; aspartate aminotransferase; CK; creatine kinase; CRC; colorectal cancer; CUHK; The Chinese University of Hong Kong; EMT; epithelial-mesenchymal transitions; FOLFIRI; FOL-folinic acid (leucovorin), F-fluorouracil (5-FU
Triplet (FOLFOXIRI) versus doublet (FOLFOX or FOLFIRI) backbone chemotherapy as first-line treatment of metastatic colorectal cancer: A systematic review and meta-analysis
Keywords: Metastatic colorectal cancer; Triplet chemotherapy; FOLFOXIRI; Doublet chemotherapy; FOLFOX; FOLFIRI;
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)
Keywords: Panitumumab; FOLFOX; FOLFIRI; Metastatic colorectal cancer; First-line; Liver-limited disease; Resection;
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
Keywords: ABCC1/MRP; ATP binding cassette subfamily C member 1/ multidrug resistance protein; ABVD; doxorubicine-bleomycin-vinblastine-dacarbazine; AC; doxorubicin-cyclophosphamide; ANC; absolute neutrophil count; ASCO; American Society of Clinical Oncology; AUC; a
Quality of Life Analysis in Patients With RAS Wild-Type Metastatic Colorectal Cancer Treated With First-Line Cetuximab Plus Chemotherapy
Keywords: CRYSTAL; FOLFIRI; Global health status (GHS); mCRC; QoL;
Quality of life analysis in patients with KRAS wild-type metastatic colorectal cancer treated first-line with cetuximab plus irinotecan, fluorouracil and leucovorin
Keywords: Cetuximab; FOLFIRI; KRAS wild-type; Metastatic colorectal cancer; Quality of life;
FOLFIRI-Bevacizumab As First-Line Chemotherapy in 3500 Patients With Advanced Colorectal Cancer: A Pooled Analysis of 29 Published Trials
Keywords: Bevacizumab; Chemotherapy; Colorectal cancer; FOLFIRI; First line
Transarterial Chemoembolization with Irinotecan Beads in the Treatment of Colorectal Liver Metastases: Systematic Review
Keywords: CR; complete response; CRLM; colorectal liver metastasis; DEB; drug-eluting bead; DEBIRI; drug-eluting beads with irinotecan; 5-FU; 5-fluorouracil; FOLFIRI; 5-fluorouracil/leucovorin/irinotecan; FOLFOX; 5-fluorouracil/leucovorin/oxaliplatin; OS; overall s
Transcatheter Arterial Chemoembolization Using Cisplatin Powder Mixed with Degradable Starch Microspheres for Colorectal Liver Metastases after FOLFOX Failure: Results of a Phase I/II Study
Keywords: ALT; alanine aminotransferase; AST; aspartate aminotransferase; CEA; carcinoembryonic antigen; CI; confidence interval; DLT; dose-limiting toxicity; DSM; degradable starch microspheres; 5-FU; 5-fluorouracil; FOLFIRI; 5-FU, leucovorin plus irinotecan; FOLF
Cancer Concepts and Principles: Primer for the Interventional Oncologist-Part II
Keywords: AFP; α-fetoprotein; AJCC; American Joint Committee on Cancer; BCLC; Barcelona Clinic Liver Cancer; CapeOx; capecitabine/oxaliplatin; CRC; colorectal cancer; DEB; drug-eluting bead; DEBIRI; drug-eluting beads with irinotecan; EASL; European Association fo
Development of a Research Agenda for the Management of Metastatic Colorectal Cancer: Proceedings from a Multidisciplinary Research Consensus Panel
Keywords: AHRQ; Agency for Healthcare Research and Quality; CLM; colorectal liver metastases; CRC; colorectal cancer; DEBIRI; drug-eluting beads loaded with irinotecan; FLR; future liver remnant; FOLFIRI; folinic acid/5-fluorouracil/irinotecan [systemic chemotherap
Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis
Keywords: Second-line chemotherapy; Colorectal cancer; Irinotecan; FOLFIRI; Randomised phase II trial;
Targeted Therapies as Adjuvant Treatment for Early-Stage Colorectal Cancer: First Impressions and Clinical Questions
Keywords: Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; KRAS; XelOx
A Randomized, Placebo-Controlled Phase II Study Evaluating the Reduction of Neutropenia and Febrile Neutropenia in Patients With Colorectal Cancer Receiving Pegfilgrastim With Every-2-Week Chemotherapy
Keywords: FOIL; FOLFIRI; FOLFOX4; Granulocyte colony-stimulating factor; Irinotecan; Oxaliplatin
The Timing of Chemotherapy and Surgery for the Treatment of Colorectal Liver Metastases
Keywords: Bevacizumab; Cetuximab; FOLFIRI; FOLFOX; FOLFOXIRI; Neoadjuvant chemotherapy
Colorectal Cancer Cell Lines Lack the Molecular Heterogeneity of Clinical Colorectal Tumors
Keywords: 5-Fluorouracil; Clustering; FOLFIRI; Gene expression profiling; Microarray; Oxaliplatin;
KRAS Mutation Screening in Colorectal Cancer: From Paper to Practice
Keywords: Cetuximab; EGFR; FOLFIRI; FOLFOX; Panitumumab
Dendritic cell vaccine in addition to FOLFIRI regimen improve antitumor effects through the inhibition of immunosuppressive cells in murine colorectal cancer model
Keywords: FOLFIRI; DC vaccine; Myeloid-derived suppressor cells; Regulatory T cells; Carcinoembryonic antigen
Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG)
Keywords: FOLFOXIRI; FOLFIRI; Elderly patients; CRC; Phase III study
Sequential or combination chemotherapy for a patient with mCRC?
Keywords: Bevacizumab; Capecitabine; Inductive chemotherapy; FOLFIRI; XELIRI
Reviews in Basic and Clinical GastroenterologySystemic Treatment of Colorectal Cancer
Keywords: ECOG; Eastern Cooperative Oncology Group; EGFR; epidermal growth factor receptor; FOLFIRI; infusional fluorouracil, leucovorin, and irinotecan; FOLFOX; infusional fluorouracil, leucovorin, and oxaliplatin; IFL; irinotecan, bolus fluorouracil, and leucovor
Update for Surgeons: Recent and Noteworthy Changes in Therapeutic Regimens for Cancer of the Colon and Rectum
Keywords: bFOL; bolus FOLFOX; CapeOx; capecitabine plus oxaliplatin; CRC; colorectal cancer; EGFR; epidermal growth factor receptor; FOLFIRI; 5-FU and irinotecan; FOLFOX; 5-FU, leucovorin, and oxaliplatin; IFL; 5-FU and leucovorin combined with irinotecan; IROX; ir
Colorectal Cancer
Keywords: CALGB; Cancer and Leukemia Group B; CRC; colorectal cancer; DFS; disease-free survival; ECOG; Eastern Cooperative Oncology Group; EGFR; epithelial growth factor receptor; FLOX; fluorouracil bolus, leucovorin with oxaliplatin; FOLFIRI; folinic acid with in
Advances in Chemotherapy for Colorectal Cancer
Keywords: APR; abdominoperineal resection; CALGB; Cancer and Leukemia Group B; CAPIRI; capecitabine and irinotecan; CAPOX; capecitabine and oxilaplatin; CRC; colorectal cancer; DFS; disease-free survival; EGFR; epidermal growth factor receptor; 5-FU; 5-fluorouracil
Phase I/II Dose-Escalation Study of Pemetrexed plus Irinotecan in Patients with Advanced Colorectal Cancer
Keywords: Combination therapy; FOLFIRI; Metastases; Vitamin supplementation;